{"id":44382,"date":"2026-03-20T09:28:30","date_gmt":"2026-03-20T09:28:30","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/44382\/"},"modified":"2026-03-20T09:28:30","modified_gmt":"2026-03-20T09:28:30","slug":"novo-nordisk-on-glp-1-generics","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/44382\/","title":{"rendered":"Novo Nordisk on GLP-1 generics"},"content":{"rendered":"<p>ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email<\/p>\n<p>The patent on semaglutide, found in Novo Nordisk&#8217;s Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how generics could reshape the market. He says he does expect drugs in India need an &#8216;Indian centric&#8217; pricing to make them more accessible.<\/p>\n","protected":false},"excerpt":{"rendered":"ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The patent on semaglutide, found&hellip;\n","protected":false},"author":2,"featured_media":44383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1275,8729,272,1273,6804,277],"class_list":{"0":"post-44382","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-business-news","9":"tag-neutral","10":"tag-novo-nordisk","11":"tag-novo-nordisk-a-s","12":"tag-patents","13":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116260798843610290","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/44382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=44382"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/44382\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/44383"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=44382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=44382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=44382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}